According to FutureWise analysis, the market for Nuclear Medicine Or Radiopharmaceuticals in 2023 is US$ 5.5 billion, and is expected to reach US$ 13.16 billion by 2031 at a CAGR of 11.50%.
A family of radioactive chemicals known as radiopharmaceuticals can be used for medicinal or diagnostic purposes. While substances that produce Auger electrons or alpha particles are often used for therapeutic purposes, substances that release beta particles (positrons or electrons) or gamma rays are frequently used for diagnostic purposes. Compared to therapeutic radiopharmaceuticals, diagnostic radiopharmaceuticals contain less radiation. Radiopharmaceuticals are special medicinal mixtures that have radioisotopes. Both diagnosis and treatment involve the use of these radiopharmaceuticals.
Medications with a high level of radioactivity are referred to as radiopharmaceuticals. A radioactive isotope-based pharmaceutical formulation known as radiopharmaceutical can be administered intravenously, orally, or interstitially. Additionally, it aids in diagnosis and is an appropriate and safer alternative for patients compared to X-Rays and other external radiation imaging systems. Radiopharmaceuticals and nuclear medicine are increasingly used in radiotherapy and diagnostic imaging. The market for radiopharmaceuticals has expanded as a result of this. Nuclear medicine and radiopharmaceuticals aid in the diagnosis of any diseased condition, including cancer, in the organs. The vast advancement in nuclear imaging technology, particularly PET/PET-CT, has expanded the range of applications for this modality from oncology to cardiology, neurology, and infection detection.
FutureWise Market Research has published a report that provides an insightful analysis of nuclear medicine or radiopharmaceuticals market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.
According to the analysis conducted by FutureWise research analysts, the nuclear medicine or radiopharmaceuticals market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.